Differentiating Factors Between Erythropoiesis-Stimulating AgentsA Guide to Selection for Anaemia of Chronic Kidney Disease

被引：0
|
作者：
Robert Deicher
Walter H. Hörl
机构：
[1] University of Vienna,Division of Nephrology and Dialysis, Department of Medicine III
[2] Universitätsklinik für Innere Medizin III,Klinische Abteilung für Nephrologie und Dialyse
来源：
Drugs | 2004年 / 64卷
关键词：
Chronic Kidney Disease; Subcutaneous Administration; Peritoneal Dialysis Patient; Sialic Acid Residue; Erythropoiesis Stimulate Agent;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Endogenous erythropoietin (EPO) consists of a central polypeptide core covered by post-translationally linked carbohydrates. Three of the four currently available erythropoiesis stimulating agents (ESA) — epoetin-α, epoetin-β and epoetin-ω — are composed of an identical amino acid sequence, but glycosylation varies as a result of type- and host cell-specific differences in the production process.
引用
收藏
页码：499 / 509
页数：10
相关论文
共 50 条
  • [21] Safety issues related to erythropoiesis-stimulating agents used to treat anemia in patients with chronic kidney disease
    Del Vecchio, Lucia
    Locatelli, Francesco
    EXPERT OPINION ON DRUG SAFETY, 2012, 11 (06) : 923 - 931
  • [22] Treatment of Anaemia with Erythropoiesis-Stimulating Agents in Patients with Chronic Kidney Disease Does Not Lower Mortality and May Increase Cardiovascular Risk: A Meta-Analysis
    Vinhas, J.
    Barreto, C.
    Assuncao, J.
    Parreira, L.
    Vaz, A.
    NEPHRON CLINICAL PRACTICE, 2012, 121 (3-4): : C95 - C101
  • [23] Soluble Fas affects erythropoiesis in vitro and acts as a potential predictor of erythropoiesis-stimulating agent therapy in patients with chronic kidney disease
    Chiloff, Daniela Mendes
    de Almeida, Danilo Candido
    Dalboni, Maria A.
    Canziani, Maria Eugenia
    George, Sunil K.
    Morsi, Alshaimaa Mahmoud
    El-Akabawy, Nadia
    Porada, Christopher D.
    Durao, Marcelino Souza
    Zarjou, Abolfazl
    Almeida-Porada, Graca
    Goes, Miguel Angelo
    AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2020, 318 (04) : F861 - F869
  • [24] Treatment of renal anaemia with erythropoiesis-stimulating agents in predialysis chronic kidney disease patients: Haemoglobin profile during the 6 months before initiation of dialysis
    Kawahara, Kazuhiko
    Minakuchi, Jun
    Yokota, Narushi
    Suekane, Hiroto
    Tsuchida, Kenji
    Kawashima, Shu
    NEPHROLOGY, 2015, 20 : 29 - 32
  • [25] Initiation of erythropoiesis-stimulating agents and outcomes: a nationwide observational cohort study in anaemic chronic kidney disease patients
    Evans, Marie
    Carrero, Juan-Jesus
    Bellocco, Rino
    Barany, Peter
    Qureshi, Abdul R.
    Seeberger, Astrid
    Jacobson, Stefan H.
    Hylander-Rossner, Britta
    Rotnitzky, Andrea
    Sjolander, Arvid
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32 (11) : 1892 - 1901
  • [26] Erythropoiesis-Stimulating Agents (ESA) for Preventing the Progression of Chronic Kidney Disease: A Meta-Analysis of 19 Studies
    Covic, Adrian
    Nistor, Ionut
    Donciu, Mihaela-Dora
    Dumea, Raluca
    Bolignano, Davide
    Goldsmith, David
    AMERICAN JOURNAL OF NEPHROLOGY, 2014, 40 (03) : 263 - 279
  • [27] Are there advantages of daprodustat over erythropoiesis-stimulating agents (ESAs) in treating anemia associated with chronic kidney disease (CKD)?
    Doggrell, Sheila A.
    EXPERT OPINION ON PHARMACOTHERAPY, 2022, 23 (07) : 769 - 773
  • [28] Association between serum hepcidin-25 and primary resistance to erythropoiesis-stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial
    Gummer, Joel
    Trengove, Robert
    Pascoe, Elaine M.
    Badve, Sunil V.
    Cass, Alan
    Clarke, Philip
    McDonald, Stephen P.
    Morrish, Alicia T.
    Pedagogos, Eugenie
    Perkovic, Vlado
    Reidlinger, Donna
    Scaria, Anish
    Walker, Rowan
    Vergara, Liza A.
    Hawley, Carmel M.
    Johnson, David W.
    Olynyk, John K.
    Ferrari, Paolo
    NEPHROLOGY, 2017, 22 (07) : 548 - 554
  • [29] Statin therapy and erythropoiesis-stimulating agent hyporesponsiveness in patients with nondialysis chronic kidney disease A retrospective study in Beijing, China
    Sui, Zhun
    Wang, Mi
    Zuo, Li
    MEDICINE, 2019, 98 (02)
  • [30] Effects of Anemia Correction by Erythropoiesis-Stimulating Agents on Cardiovascular Function in Non-Dialysis Patients With Chronic Kidney Disease
    Suzuki, Makoto
    Hada, Yoshiyuki
    Akaishi, Makoto
    Hiroe, Michiaki
    Aonuma, Kazutaka
    Tsubakihara, Yoshiharu
    Akizawa, Tadao
    INTERNATIONAL HEART JOURNAL, 2012, 53 (04) : 238 - 243
12345